DailyIQ
|
Sector:HealthcareAll sectors
Last updated just now

ALGN·Align Technology, Inc.

$.
-. (-.%)
After Hours
High
$166.00
Open
$164.97
Market Cap
11.72B
52W High
$208.31
Low
$162.32
P. Close
$163.53
P/E
27.26
52W Low
$122.00
Fwd P/E
13.23
Mean Target
$209.07
Technical Score (1D)
23
SELL
News Sentiment
73
BULLISH
Align Technology is making a significant investment of $200 million to build a new clear-aligner manufacturing facility in Hyderabad, India, with an expected opening in 2027. This strategic move, which will create over 300 jobs, aims to enhance the company's global supply chain and manufacturing efficiency. The establishment of this facility signals a long-term capacity and cost-efficiency strategy, potentially reshaping Align's narrative around global expansion. Investors will be watching how this integration of Indian operations impacts overall production capabilities and cost structures in the coming years.
Earnings Summary
Align Technology is a global medical device company focused on digital dentistry solutions, primarily known for its Invisalign clear aligners and iTero intraoral scanners. Operating within the Healthcare sector, specifically Medical Instruments & Supplies, Align's innovative technology facilitates digital workflows for orthodontists and dentists worldwide. The company's core offerings aim to enhance patient outcomes and streamline treatment processes. In its recent earnings performance, Align Technology has shown a trend of exceeding analyst expectations for earnings per share. For Q1 2026, the company reported actual EPS of $2.58, surpassing the estimated $2.3251, with revenue of $1.04 billion meeting the estimate of $1.042 billion. This follows a strong Q4 2025 where actual EPS of $3.29 beat the estimate of $3.031, and revenue of $1.047 billion slightly missed the estimate of $1.053 billion. Reviewing the prior two quarters, Q3 2025 saw actual EPS of $2.61 beat the estimate of $2.40853, with revenue at $995.69 million. Q2 2025 reported actual EPS of $2.49, missing the estimate of $2.57381, while revenue was $1.012 billion. Historically, Align has demonstrated a consistent pattern of beating EPS estimates in most recent quarters, including Q4 2024, Q1 2025, Q3 2025, Q4 2025, and Q1 2026, with a miss in Q2 2025. Revenue has generally trended upwards, with slight fluctuations. Recent news indicates Align Technology is participating in upcoming financial conferences, providing opportunities for management to discuss strategy and performance via webcast. The company is also being recognized as a top value stock for long-term investors, suggesting a positive outlook on its fundamentals and market position. Investors will be watching for updates from these conferences and continued evidence of sustained growth and market leadership in the upcoming reporting periods.

EPS

EstBeatMiss
$1.79$2.22$2.64$3.06$3.49Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.61 - -
Q1'26$2.33$2.58+11.0%
Q4'25$3.03$3.29+8.5%
Q3'25$2.41$2.61+8.4%
Q2'25$2.57$2.49-3.3%
Q1'25$1.99$2.13+7.1%

Revenue

EstBeatMiss
$964M$997M$1.0B$1.1B$1.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.1B - -
Q1'26$1.0B$1.0B-0.2%
Q4'25$1.1B$1.0B-0.6%
Q3'25 - $996M -
Q2'25 - $1.0B -
Q1'25 - $979M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ALGN Stock Snapshot

ALGN is currently trading at $163.55, giving Align Technology, Inc. a market cap of 11.72B and a P/E ratio of 27.3. Today's range spans $162.32–$166.00, with shares opening at $164.97 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 73/100.

Over the past year ALGN has traded between $122.00 and $208.31 - the current price is +34.1% off the 52-week low and -21.5% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $209.07 (range $175.00–$240.00), implying upside of +27.8%.

When ALGN shows a SELL (23/100) alongside bullish sentiment (73/100), the right posture for most Healthcare investors is reduced exposure rather than conviction buying. Price: $163.55 (in the middle of its 52-week range). (P/E: 27.3) At 11.72B in capitalization, the structural support levels within the $122.00–$208.31 annual range are where the setup becomes reassessable - not before.

When a large-cap Healthcare name with 11.72B in capitalization prints a SELL signal (23/100) alongside bullish news sentiment (73/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $163.55 (in the middle of its 52-week range in the $122.00–$208.31 range), the structural support levels are where that sponsorship question gets answered.